Summary: Dr. Kaja reviews the preclinical models available for drug discovery for dry AMD and discusses the challenges and opportunities associated with them.
Content
How to choose a preclinical model for proof-of-concept and pharmacologic efficacy studies in dry AMD? What about imaging modalities available to monitor dry AMD pathology?
Dr. Simon Kaja, CSO of Experimentica, will address these questions – and others – during his presentation at Dry AMD Therapeutics Summit on October 28, 2020.
Register here to attend the session.
